Prediction of Adverse Outcomes in Pediatric Acute Hematogenous Osteomyelitis.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
03 12 2020
Historique:
received: 07 11 2019
accepted: 28 02 2020
pubmed: 5 3 2020
medline: 28 4 2021
entrez: 5 3 2020
Statut: ppublish

Résumé

Clinicians cannot reliably predict complications of acute hematogenous osteomyelitis (AHO). Consecutive cases of AHO from 2 pediatric centers in the United States were analyzed retrospectively to develop clinical tools from data obtained within 96 hours of hospitalization to predict acute and chronic complications of AHO. Two novel composite prediction scores derived from multivariable logistic regression modeling were compared with a previously published severity of illness (SOI) score, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) using area under the receiver operating characteristic curve analyses. The causative organisms were identified in 73% of 261 cases. Bacteremia (45%), abscesses (38%), and associated suppurative arthritis (23%) were relatively common. Acute or chronic complications occurred in 24% and 11% of patients, respectively. Multivariable logistic regression identified bone abscess (odds ratio [OR], 2.3 [95% confidence interval {CI}, 1.0-5.2]), fever > 48 hours (OR, 2.7 [95% CI, 1.2-6.0]), suppurative arthritis (OR, 3.2 [95% CI, 1.3-7.5]), disseminated disease (OR, 4.6 [95% CI, 1.5-14.3]), and delayed source control (OR, 5.1 [95% CI, 1.4-19.0]) as strong predictors of acute complications. In a separate model, CRP ≥ 100 mg/L at 2-4 days after antibiotics (OR, 2.7 [95% CI, 1.0-7.3]), disseminated disease (OR, 3.3 [95% CI, 1.1-10.0]), and requirement for bone debridement (OR, 6.7 [95% CI, 2.1-21.0]) strongly predicted chronic morbidity. These variables were combined to create weighted composite prediction scores for acute (A-SCORE) and chronic (C-SCORE) osteomyelitis, which were superior to SOI, CRP, and ESR and had negative predictive values > 90%. Two novel composite clinical scores were superior to existing tools to predict complications of pediatric AHO.

Sections du résumé

BACKGROUND
Clinicians cannot reliably predict complications of acute hematogenous osteomyelitis (AHO).
METHODS
Consecutive cases of AHO from 2 pediatric centers in the United States were analyzed retrospectively to develop clinical tools from data obtained within 96 hours of hospitalization to predict acute and chronic complications of AHO. Two novel composite prediction scores derived from multivariable logistic regression modeling were compared with a previously published severity of illness (SOI) score, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) using area under the receiver operating characteristic curve analyses.
RESULTS
The causative organisms were identified in 73% of 261 cases. Bacteremia (45%), abscesses (38%), and associated suppurative arthritis (23%) were relatively common. Acute or chronic complications occurred in 24% and 11% of patients, respectively. Multivariable logistic regression identified bone abscess (odds ratio [OR], 2.3 [95% confidence interval {CI}, 1.0-5.2]), fever > 48 hours (OR, 2.7 [95% CI, 1.2-6.0]), suppurative arthritis (OR, 3.2 [95% CI, 1.3-7.5]), disseminated disease (OR, 4.6 [95% CI, 1.5-14.3]), and delayed source control (OR, 5.1 [95% CI, 1.4-19.0]) as strong predictors of acute complications. In a separate model, CRP ≥ 100 mg/L at 2-4 days after antibiotics (OR, 2.7 [95% CI, 1.0-7.3]), disseminated disease (OR, 3.3 [95% CI, 1.1-10.0]), and requirement for bone debridement (OR, 6.7 [95% CI, 2.1-21.0]) strongly predicted chronic morbidity. These variables were combined to create weighted composite prediction scores for acute (A-SCORE) and chronic (C-SCORE) osteomyelitis, which were superior to SOI, CRP, and ESR and had negative predictive values > 90%.
CONCLUSIONS
Two novel composite clinical scores were superior to existing tools to predict complications of pediatric AHO.

Identifiants

pubmed: 32129457
pii: 5780104
doi: 10.1093/cid/ciaa211
pmc: PMC7904074
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e454-e464

Subventions

Organisme : NIAID NIH HHS
ID : R25 AI140490
Pays : United States

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Orthop Clin North Am. 2017 Apr;48(2):181-197
pubmed: 28336041
Lancet Infect Dis. 2016 Aug;16(8):e139-52
pubmed: 27321363
J Pediatr Orthop. 2018 May/Jun;38(5):e285-e291
pubmed: 29462119
Lancet. 1988 Jan 2-9;1(8575-6):37-40
pubmed: 2891899
Infect Dis Clin North Am. 2015 Sep;29(3):557-74
pubmed: 26311358
Pediatr Infect Dis J. 2017 Jun;36(6):572-577
pubmed: 28027279
J Pediatr Orthop. 2019 Feb;39(2):90-97
pubmed: 27741035
JAMA Pediatr. 2015 Jul;169(7):698-9
pubmed: 26147054
Scand J Infect Dis. 2012 Sep;44(9):683-8
pubmed: 22568753
Curr Opin Pediatr. 2013 Feb;25(1):58-63
pubmed: 23283291
Clin Infect Dis. 2019 Nov 13;69(11):1955-1961
pubmed: 30753346
J Bone Joint Surg Am. 2013 Apr 17;95(8):686-93
pubmed: 23595066
Clin Infect Dis. 2011 Feb 1;52(3):e18-55
pubmed: 21208910
Open Forum Infect Dis. 2019 Apr 08;6(5):ofz181
pubmed: 31123692
BMC Infect Dis. 2002 Aug 14;2:16
pubmed: 12181082
N Engl J Med. 2014 Jan 23;370(4):352-60
pubmed: 24450893
J Pediatr Orthop. 2002 May-Jun;22(3):317-20
pubmed: 11961446
J Pediatr Orthop. 2009 Jul-Aug;29(5):518-25
pubmed: 19568027
Pediatr Infect Dis J. 2014 Jan;33(1):35-41
pubmed: 24352188
J Pediatr Orthop. 2018 May/Jun;38(5):279-286
pubmed: 27299780
J Pediatr Orthop. 2016 Mar;36(2):173-7
pubmed: 25929777
Clin Infect Dis. 1997 May;24(5):849-53
pubmed: 9142781
Orthop Clin North Am. 2017 Apr;48(2):199-208
pubmed: 28336042
Clin Microbiol Infect. 2016 Jul;22(7):643.e1-6
pubmed: 27107685
Arch Pediatr. 2017 Dec;24(12S):S36-S41
pubmed: 29290233
Pediatr Infect Dis J. 2017 Aug;36(8):788-799
pubmed: 28708801
J Pediatr. 1978 Mar;92(3):485-90
pubmed: 632997
Pediatrics. 2006 Feb;117(2):433-40
pubmed: 16452363
Pediatr Infect Dis J. 2016 Apr;35(4):387-91
pubmed: 26669740
Pediatrics. 2009 Feb;123(2):636-42
pubmed: 19171632
JAMA Pediatr. 2015 Feb;169(2):120-8
pubmed: 25506733
Pediatr Infect Dis J. 2012 May;31(5):519-21
pubmed: 22189533
Pediatrics. 2012 Oct;130(4):e821-8
pubmed: 22966033
Front Microbiol. 2017 Nov 28;8:2355
pubmed: 29234317
Pediatr Infect Dis J. 2010 Dec;29(12):1123-8
pubmed: 20842069
Paediatr Child Health. 2018 Aug;23(5):336-343
pubmed: 30653632
Front Cell Infect Microbiol. 2015 Nov 26;5:85
pubmed: 26636047
Clin Pediatr (Phila). 2007 Jan;46(1):30-5
pubmed: 17164506
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530845

Auteurs

Zaid Alhinai (Z)

Department of Pediatrics, Division of Infectious Diseases, Warren Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.

Morvarid Elahi (M)

Department of Pediatrics, Divisions of Neonatology and Pediatric Infectious Diseases, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, USA.

Sangshin Park (S)

Graduate School of Urban Public Health, University of Seoul, Seoul, Republic of Korea.

Bill Foo (B)

Department of Pediatrics, Division of Hospital Medicine, Warren Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.

Brian Lee (B)

Department of Pediatrics, Division of Hospital Medicine, Warren Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.

Kimberle Chapin (K)

Department of Pathology and Laboratory Medicine, Laboratory of Clinical Microbiology, Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, Rhode Island, USA.

Michael Koster (M)

Department of Pediatrics, Division of Hospital Medicine, Warren Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.

Pablo J Sánchez (PJ)

Department of Pediatrics, Divisions of Neonatology and Pediatric Infectious Diseases, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, USA.

Ian C Michelow (IC)

Department of Pediatrics, Division of Infectious Diseases, Warren Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH